Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis

Proteins: Structure, Function and Bioinformatics

Volumn 83, Issue 5, 2015, Pages 898-909

  Prakash, Priyanka ^a   Hancock, John F ^a   Gorfe, Alemayehu A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Allosteric sites; Drug design; Probe based molecular dynamics simulation

Indexed keywords

BENZIMIDAZOLE; IMIDAZOLE; INDOLE; K RAS PROTEIN; LIGAND; KRAS PROTEIN, HUMAN; MOLECULAR PROBE; ONCOPROTEIN; PROTEIN BINDING; PROTEIN P21; RAS PROTEIN;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE BINDING SITE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; PROTEIN SECONDARY STRUCTURE;

CATALYTIC DOMAIN; HUMANS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR PROBES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS;

EID: 84927690758     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24786     Document Type: Article

References (69)

1. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
2. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-531.
3. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010;1:2-27.
4. ras to the plasma membrane. Cell 1990;63:133-139.
5. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
6. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. Ras oncogenes: weaving a tumorigenic web. Nat Rev 2011;11:761-774.
7. Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Can Res 2012;72:2457-2467.
8. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298-303.
9. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
10. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
11. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
12. Gorfe AA. Mechanisms of allostery and membrane attachment in ras GTPases: implications for anti-cancer drug discovery. Curr Med Chem 2010;17:1-9.
13. Baines AT, Xu D, Der CJ. Inhibition of ras for cancer treatment: the search continues. Future Med Chem 2011;3:1787-1808.
14. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001;294:1299-1304.
15. 15N resonance assignment for the human K-ras at physiological pH. Biomol NMR Assign 2013;7:215-219.
16. Araki M, Shima F, Yoshikawa Y, Muraoka S, Ijiri Y, Nagahara Y, Shirono T, Kataoka T, Tamura A. Solution stucture of the state 1 conformer of GTP-bound H-ras protein and distinct dynamic properties between the state 1 and state 2 conformers. J Biol Chem 2011;286:39644-39653.
17. Prakash P, Gorfe AA. Lessons from computer simulations of ras proteins in solution and in membrane. Biochim Biophys Acta 2013;1830:5211-5218.
18. Prakash P, Gorfe AA. Overview of simualtion studies on the enzymatic activity and conformational dynamics of the GTPase ras. Mol Sim 2014;40:839-847.
19. Gorfe AA, Hanzal-Bayer M, Abankwa D, Hancock JF, McCammon JA. Structure and dynamics of the full-length lipid-modified H-ras protein in a 1, 2-dimyristoylglycero-3-phosphocholine bilayer. J Med Chem 2007;50:674-684.
20. Gorfe AA, Grant BJ, McCammon JA. Mapping the nucleotide and isoform-dependent structural and dynamical features of ras proteins. Structure 2008;16:885-896.
21. Grant BJ, Gorfe AA, McCammon JA. Ras conformational switching: simulating nucleotide-dependent conformational transitions with accelerated molecular dynamics. PLoS Comput Biol 2009;5:e1000325
22. Buhrman G, Holzapfel G, Fetics S, Mattos C. Allosteric modulation of ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci USA 2010;107:4931-4936.
23. Grant BJ, McCammon JA, Gorfe AA. Conformational selection in G proteins: lessons from ras and rho. Biophys J 2010;99:L87-L89.
24. Grant BJ, Lukman S, Hocker HJ, Sayyah J, Brown JH, McCammon JA, Gorfe AA. Novel allosteric sites on ras for lead generation. PLoS One 2011;6:e25711
25. Buhrman G, O'Connor C, Zerbe B, Kearney BM, Napoleon R, Kovrigina EA, Vajda S, Kozakov D, Kovrigin EL, Mattos C. Analysis of binding site hot spots on the surface of ras GTPase. J Mol Biol 2011;413:773-789.
26. Hocker HJ, Cho KJ, Chen CY, Rambahal N, Sagineedu SR, Sharri K, Stanslas J, Hancock JF, Gorfe AA. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic ras function. Proc Natl Acad Sci USA 2013;110:10201-10206.
27. Hocker HJ, Rambahal N, Gorfe AA. LIBSA-a method for the determination of ligand-binding preference to allosteric sites on receptor ensembles. J Chem Inf Model 2014;54:530-538.
28. Rosnizeck IC, Graf T, Spoerner M, Tränkle J, Filchtinski D, Herrmann C, Gremer L, Vetter IR, Wittinghofer A, König B, Kalbitzer HR. Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes. Angew Chem Int Ed Engl 2010;49:3830-3833.
29. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G. Small-molecule ligands bind to a distinct pocket in ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci USA 2012;109:5299-5304.
30. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. Discovery of small molecules that bind to K-ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012;51:6140-6143.
31. Rosnizeck IC, Spoerner M, Harsch T, Kreitner S, Filchtinski D, Herrmann C, Engel D, König B, Kalbitzer HR. Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated ras protein. Angew Chem Int Ed Engl 2012;51:10647-10651.
32. Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, Nishiyama Y, Sato C, Muraoka S, Tamura A, Osoda T, Tsuda KI, Miyakawa T, Fukunishi H, Shimada J, Kumasaka T, Yamamoto M, Kataoka T. In silico discovery of small-molecule ras inhibitors that display antitumor activity by blocking the ras-effector interaction. Proc Natl Acad Sci USA 2013;110:8182-8187.
33. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. KRas(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-551.
34. Sun Q, Phan J, Friberg AR, Camper DV, Olejniczak ET, Fesik SW. A method for the second-site screening of K-ras in the presence of a covalently attached first-site ligand. J Biomol NMR 2014;60:11-14.
35. Inouye K, Mizutani S, Koide H, Kaziro Y. Formation of the ras dimer is essential for Raf-1 activation. J Biol Chem 2000;275:3737-3740.
36. Tian T, Harding A, Inder K, Plowman S, Parton RG, Hancock JF. Plasma membrane nanoswitches generate high-fidelity ras signal transduction. Nat Cell Biol 2007;9:905-914.
37. Abankwa D, Gorfe AA, Hancock JF. Ras nanoclusters: molecular structure and assembly. Semin Cell Dev Biol 2007;18:599-607.
38. Güldenhaupt J, Rudack T, Bachler P, Mann D, Triola G, Waldmann H, Kötting C, Gerwert K. NRas forms dimers at POPC membranes. Biophys J 2012;103:1585-1593.
39. Cho KJ, Hancock JF. Ras nanoclusters: a new drug target? Small GTPases 2013;4:57-60.
40. Lin WC, Iversen L, Tu HL, Rhodes C, Christensen SM, Iwig JS, Hansen SD, Huang WY, Groves JT. HRas forms dimers on membrane surfaces via a protein-protein interface. Proc Natl Acad Sci USA 2014;111:2996-3001.
41. Zhou Y, Hancock JF. Ras nanoclusters: versatile lipid-based signaling platforms. Biochim Biophys Acta 2015;1853:841-849.
42. Seco J, Luque FJ, Barril X. Binding site detection and druggability index from first principles. J Med Chem 2009;52:2363-2371.
43. Guvench O, MacKerell AD. Computational Fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol 2009;5:e1000435
44. Raman EP, Yu W, Guvench O, MacKerell AD. Reproducing crystal binding modes of ligand functional groups using Site-identification by ligand competitive saturation (SILCS) simulations. J Chem Inf Model 2011;51:877-896.
45. Bakan A, Nevins N, Lakdawala AS, Bahar I. Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules. J Chem Theory Comput 2012;8:2435-2447.
46. Allen KN, Bellamacina CR, Ding X, Jeffery CJ, Mattos C, Petsko GA, Ringe D. An experimental approach to mapping the binding surfaces of crystalline proteins. J Phys Chem 1996;100:2605-2611.
47. Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005;48:2518-2525.
48. Brenke R, Kozakov D, Chuang GY, Beglov D, Hall D, Landon MR, Mattos C, Vajda S. Fragment-based identification of druggable 'hot spots' of proteins using fourier domain correlation techniques. Bioinformatics 2009;25:621-627.
49. Laskowski RA. SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interaction. J Mol Graph 1995;13:323-330.
50. Huang B, Schroeder M. LIGSITEcsc: predicting ligand binding sites using the connolly surface and degree of conservation. BMC Struct Biol 2006;6:19
51. Schmidtke P, Bidon-Chanal A, Luque FJ, Barril X. MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics 2011;27:3276-3285.
52. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781-1802.
53. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FT, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998;102: 3586-3616.
54. Mackerell AD, Feig M, Brooks CL. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 2004;25:1400-1415.
55. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I, MacKerell AD. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 2010;31:671-690.
56. Yu W, He X, Vanommeslaeghe K, MacKerell AD. Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J Comput Chem 2012;33:2451-2468.
57. Darden T, York D, Pedersen L. Particle mesh ewald: an nlog(N) method for ewald sums in large systems. J Chem Phys 1993;98:10089-10092.
58. Tan YS, Śledź P, Lang S, Stubbs CJ, Spring DR, Abell C, Best RB. Using Ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of Polo-like kinase 1. Angew Chem Int Ed Engl 2012;51:10078-10081.
59. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-38.
60. Upadhyaya P, Qian Z, Habir NA, Pei D. Direct ras inhibitors identified from a structurally rigidified bicyclic peptide library. Tetrahedron 2014;70:7714-7720.
61. Lee GM, Craik CS. Trapping moving targets with small molecules. Science 2009;324:213-215.
62. Prakash P, Sayyed-Ahmad A, Gorfe AA. The role of conserved waters in conformational transitions of Q61H K-ras. PLoS Comput Biol 2012;8:e1002394
63. Buck M, Bouguet-Bonnet S, Pastor RW, MacKerell AD. Importance of the CMAP correction to the CHARMM22 protein force field: dynamics of hen lysozyme. Biophys J 2006;90:L36-L38.
64. Shima F, Ijiri Y, Muraoka S, Liao J, Ye M, Araki M, Matsumoto K, Yamamoto N, Sugimoto T, Yoshikawa Y, Kumasaka T, Yamamoto M, Tamura A, Kataoka T. Structural basis for conformational dynamics of GTP-bound ras protein. J Biol Chem 2010;285:22696-22705.
65. Spoerner M, Hozsa C, Poetzl JA, Reiss K, Ganser P, Geyer M, Kalbitzer HR. Conformational states of human rat sarcoma (ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis. J Biol Chem 2010;285:39768-39778.
66. Abankwa D, Hanzal-Bayer M, Ariotti N, Plowman SJ, Gorfe AA, Parton RG, McCammon JA, Hancock JF. A novel switch region regulates H-ras membrane orientation and signal output. EMBO J 2008;27:727-735.
67. Margarit SM, Sondermann H, Hall BE, Nagar B, Hoelz A, Pirruccello M, Bar-Sagi D, Kuriyan J. Structural evidence for feedback activation by ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 2003;112:685-695.
68. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell 2014;25:272-281.
69. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014;13:828-851.